When is glulisine taken relative to meals?

It is fast-acting and typically given shortly before a meal (or soon after) as directed by a clinician; because it works quickly, skipping the meal can cause low blood sugar.

How does glulisine differ from regular human insulin?

Glulisine is absorbed faster and acts sooner, so it matches post-meal glucose better; in trials it improved control versus regular insulin in type 2 diabetes.

Can glulisine be used as my only insulin?

No. It is short-acting and cannot provide 24-hour basal coverage; it is used with a basal insulin unless a clinician directs otherwise, and products should not be interchanged without guidance.

What is the biggest safety concern with glulisine?

Hypoglycaemia, which can be severe and can occur rapidly; injection-site reactions, weight gain and low potassium are also possible. Dosing must be individualized.

EMA-approvedaka Apidra

Insulin glulisine — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Insulin glulisine (also known as Apidra) is a peptide catalogued under Hormones & Metabolic (Rapid-acting insulin analogue). It is described as: Insulin receptor agonist. Documented context: Diabetes mellitus. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Insulin glulisine?

Insulin glulisine (brand name Apidra) is a rapid-acting, mealtime (bolus) human insulin analog created by substituting two amino acids (asparagine-B3 to lysine and lysine-B29 to glutamic acid), which speeds its absorption. It is a prescription injectable approved by the FDA and EMA (2004) for type 1 and type 2 diabetes in adults and children.

The supporting evidence is human and includes several randomized controlled trials against regular human insulin and other rapid analogues; it is used as the prandial component of basal-bolus therapy or in insulin pumps.

How does Insulin glulisine work?

The amino-acid changes reduce self-association into hexamers, so glulisine is absorbed and acts faster than regular human insulin, matching the post-meal glucose rise more closely.

Once absorbed it activates the insulin receptor, driving glucose uptake into muscle and fat and suppressing hepatic glucose production.

What does the research say about Insulin glulisine?

In type 2 diabetes, mealtime glulisine added to basal insulin improved overall and post-meal glycaemic control compared with regular human insulin. ^[1]
In type 1 diabetes, glulisine provided efficacy and safety comparable to insulin aspart as the bolus insulin. ^[2]
Glulisine worked effectively as the rapid-acting mealtime component of an optimized basal-bolus regimen in type 1 diabetes. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Insulin glulisine provides improved glycemic control in patients with type 2 diabetes — Dailey G et al., Diabetes Care 2004. (Phase III randomized controlled trial)
[2] Efficacy and safety of insulin glulisine in patients with type 1 diabetes — Dreyer M et al., Hormone and Metabolic Research 2005. (Randomized controlled trial)
[3] Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine — Garg SK et al., Endocrine Practice 2005. (Randomized controlled trial)
[4] Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes — Philotheou A et al., Diabetes Technology and Therapeutics 2011. (Randomized controlled trial)
[5] Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial — Rosenstock J et al., Diabetes Care 2016. (Randomized controlled trial)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Glulisine is injected subcutaneously around mealtimes, or delivered by insulin pump, as the bolus part of a regimen; the amount depends on the meal and glucose level and is set with a clinician. This page gives context only and not dosing instructions.

It is short-acting and cannot replace long-acting basal insulin; mixing or interchanging insulin products should only be done under professional guidance.

Side effects & safety profile

As with every insulin, hypoglycaemia is the principal and potentially serious risk of glulisine, and its fast onset means low glucose can occur quickly if a meal is delayed or skipped after dosing.

Weight gain, injection-site reactions, lipodystrophy and hypokalaemia can also occur.

Dosing is individualized and matched to carbohydrate intake, current glucose and activity by a clinician; it is typically given shortly before (or soon after) meals and must not be substituted for a basal insulin.

Stacking & combinations

Glulisine is normally combined with a long-acting basal insulin in a basal-bolus regimen under medical supervision, providing mealtime coverage alongside background insulin.

Finding Insulin glulisine vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is a rapid-acting mealtime insulin approved for type 1 and type 2 diabetes, used to cover the glucose rise from meals, usually alongside a longer-acting basal insulin.

References

[1] Insulin glulisine provides improved glycemic control in patients with type 2 diabetes — Dailey G et al., Diabetes Care 2004. PMID: 15451901. View sourceStudy: Phase III randomized controlled trialMealtime glulisine plus basal insulin improved HbA1c and postprandial glucose versus regular human insulin in type 2 diabetes.
[2] Efficacy and safety of insulin glulisine in patients with type 1 diabetes — Dreyer M et al., Hormone and Metabolic Research 2005. PMID: 16308840. View sourceStudy: Randomized controlled trialGlulisine was as effective and safe as insulin aspart for mealtime control in type 1 diabetes.
[3] Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine — Garg SK et al., Endocrine Practice 2005. PMID: 16033730. View sourceStudy: Randomized controlled trialGlulisine with glargine improved glycaemic control over regular insulin in an optimized basal-bolus regimen.
[4] Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes — Philotheou A et al., Diabetes Technology and Therapeutics 2011. PMID: 21291333. View sourceStudy: Randomized controlled trialIn children with type 1 diabetes, glulisine matched lispro for efficacy and safety in basal-bolus therapy.
[5] Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial — Rosenstock J et al., Diabetes Care 2016. PMID: 27222510. View sourceStudy: Randomized controlled trialAdding glulisine to glargine lowered HbA1c in type 2 diabetes, with more hypoglycaemia and weight gain than a GLP-1 alternative.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.